Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Labiotech.eu
labiotech.eu > best-biotech > car-t-companies-tackling-autoimmune-diseases

Eight CAR-T companies tackling autoimmune disorders

2+ hour, 20+ min ago   (568+ words) Maryland-based company Cartesian Therapeutics has merged mRNA technology with CAR-T cell therapeutics to treat autoimmune diseases. Myasthenia gravis tops the list with its candidate Descartes-08 currently in phase 3 trials. A phase 2 study found that 71% of patients with myasthenia gravis who…...

Labiotech.eu
labiotech.eu > trends-news > bipolar-disorder-therapies-biotechs

Race for approval: biotechs accelerate bipolar disorder therapies

2+ week, 6+ day ago   (586+ words) Bipolar disorder affects more than 40 million people in the world, and the depressive phase is the predominant and most disabling state for the majority of patients. It causes physical changes in the brain’s emotion control centers and the chemical messengers,…...

Labiotech.eu
labiotech.eu > best-biotech > sickle-cell-disease-company

Sickle cell disease after Casgevy: seven companies to watch in 2026

2+ mon, 4+ week ago   (1153+ words) Casgevy’s approval changed the sickle cell disease landscape. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, the therapy showed that the disease could be tackled at its genetic root, using CRISPR/Cas9 to edit a patient’s own blood stem cells and increase…...

Labiotech.eu
labiotech.eu > in-depth > brain-awareness-week-neuroscience-breakthroughs

Brain Awareness Week: cutting-edge neuroscience breakthroughs you should know

4+ mon, 2+ week ago   (560+ words) Besides new ways to manufacture already approved drugs, many new kinds of therapies are currently being tested in the clinic. Labiotech spoke to scientists developing various therapies to treat a broad range of disorders that affect the brain. The team…...

Labiotech.eu
labiotech.eu > in-depth > biotech-ophthalmology-treatment-landscape

The ophthalmology biotech landscape: promising therapies to watch

5+ mon, 2+ week ago   (1560+ words) “The protection of vision is central to the quality of human life. Even a moderate loss of visual function impacts your independence, physical safety, emotional well-being, and social participation, often more than many other chronic diseases, such as loss of…...

Labiotech.eu
labiotech.eu > opinion > precision-psychiatry-future-mental-healthcare

Precision psychiatry is the future of mental healthcare

8+ mon, 2+ week ago   (269+ words) This shift marks the rise of precision neuroscience – an emerging model of mental healthcare that uses biomarkers, brain circuits, and individualized data to guide treatment, much like precision oncology has done for cancer. The issues with the drugs themselves have…...

Labiotech.eu
labiotech.eu > more-news > excellthera-zemcelpro

ExCellThera’s first-in-class UM171 cell therapy is now approved in Europe

11+ mon, 1+ week ago   (465+ words) Two months after ExCellThera’s Zemcelpro (UM171 cell therapy) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), the European Commission granted the therapy conditional marketing authorization for adult patients with blood cancers who…...

Labiotech.eu
labiotech.eu > best-biotech > psychedelic-companies

Six psychedelic drug companies aiming to revolutionize mental health treatment

11+ mon, 3+ week ago   (706+ words) Psychedelic drugs have the potential to become an effective treatment for crippling mental health conditions such as depression. In this article, we take a look at six of the top psychedelic companies leading their particular niches in the field of…...